Health Care & Life Sciences » Pharmaceuticals | Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
11,798.00
15,470.00
7,857.00
14,006.00
7,883.00
9,656
Total Accounts Receivable
4,818.00
3,968.00
4,213.00
3,587.00
65.00
1,836
Other Current Assets
204.00
145.00
174.00
237.00
362.00
547
Total Current Assets
16,820.00
19,583.00
12,244.00
17,830.00
8,310.00
13,301
Net Property, Plant & Equipment
1,603.00
1,268.00
1,043.00
837.00
595.00
794
Total Assets
18,423.00
20,851.00
13,287.00
18,667.00
8,905.00
14,095
ST Debt & Current Portion LT Debt
-
-
-
-
3,000.00
Accounts Payable
5,118.00
4,408.00
4,158.00
3,015.00
821.00
Other Current Liabilities
5,728.00
2,254.00
695.00
1,842.00
643.00
Total Current Liabilities
10,846.00
6,662.00
4,853.00
4,857.00
4,464.00
Long-Term Debt
-
-
-
-
3,584.00
Other Liabilities
1,817.00
5,578.00
1,444.00
619.00
-
Total Liabilities
12,663.00
12,240.00
6,297.00
5,476.00
8,048.00
Common Equity (Total)
5,760.00
8,611.00
6,990.00
13,191.00
857.00
Total Shareholders' Equity
5,760.00
8,611.00
6,990.00
13,191.00
857.00
Total Equity
5,760.00
8,611.00
6,990.00
13,191.00
857.00
Liabilities & Shareholders' Equity
18,423.00
20,851.00
13,287.00
18,667.00
8,905.00

About Titan Pharmaceuticals

View Profile
Address
400 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.titanpharm.com
Updated 07/08/2019
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform.